Cincinnati Center for Eosinophilic Disorders Research
Clinical Trials

Clinical Studies and Trials for Eosinophilic Disorders

We are actively conducting research to help understand and improve outcomes for patients with eosinophilic disorders. For more information on our ongoing clinical research, open the descriptions of our clinical studies and trials below.

For research inquiries, contact the Cincinnati Center for Eosinophilic Disorders (CCED) at ccedresearch@cchmc.org.

For more of our clinical trials, visit these clinicaltrials.gov webpages:

Ongoing Clinical Studies & Trials

Study for Children, Teens and Adults 12 to 60 Years Old with Eosinophilic Gastritis

Why are we doing this research?

Cincinnati Children’s is conducting a research study, sometimes known as a clinical trial or clinical study, to test the effectiveness of a drug called Benralizumab in people diagnosed with Eosinophilic Gastritis (EoG). Benralizumab is approved by the FDA for treatment of adolescents and adults with eosinophilic asthma but not other types of eosinophilic diseases.

Who can participate?

Children, teens and adults 12 to 60 years old with EoG or with Eosinophilic Gastroenteritis (EGE) may be eligible to participate. EoG and EGE are inflammatory diseases involving a combination of gastrointestinal locations including the esophagus, stomach, and small intestine. Involvement of the stomach (EoG) is required to participate.

What will happen in the study?

There are three phases to the study. Each phase involve visits to Cincinnati Children’s Hospital Medical Center (CCHMC).

Screening phase: Involves one visit. The screening phase is to make sure you are eligible to take part in the study. It will involve an endoscopy to determine how your EoG is doing.

Treatment phase: Involves four visits. You will be assigned by chance (like the flip of a coin) to receive Benralizumab or placebo. A placebo is an inactive substance. Neither you nor your study doctor will know whether you are receiving study drug (Benralizumab) or placebo. In the case of an emergency, you and your doctor will be able to know if you have been on drug or placebo. The study drug will be given as a subcutaneous injection (an injection under the skin) once every 4 weeks for 2 months (3 total injections). An endoscopy will be done at the end of this treatment phase.

Open Label phase: Upon completion of the treatment phase, you may choose to participate in the Open Label extension phase, in which you will receive treatment with Benralizumab for an additional 24 weeks. Open Label means that there is no placebo; all participants will receive the active drug in this part of the study. There are seven visits in the Open Label phase. The first visit will include an endoscopy at CCHMC and an injection of the study drug. Three additional visits will occur at CCHMC where you will receive the study drug. Two other visits will occur over the phone. The final visit will take place at CCHMC and will include an endoscopy.

Will I need to change my diet or other medications during the study?

Throughout the study you should follow the same diet that you were following before starting the study. You may continue to take the medications that you were taking before starting the study, but try not to take any new medications or change the dose of the medications that you are taking, if possible. If there are changes to your diet or medication at any time, you should contact a study staff member.

What are the good things that can happen from this research?

We hope to learn that the study drug Benralizumb is an effective treatment for EoG and EGE. It has already been determined to be effective in the treatment of eosinophilic asthma.

What are the bad things that can happen from this research?

Possible risks and discomforts will be discussed with parents or guardians interested in learning more about the study.

Will you/your child be paid to be in this research study?

You will be paid for your time and travel expenses incurred throughout the study. You will receive $50 for each study visit including visits that take place over the phone. You will receive $100 for the visit that occurs at the end of the treatment phase. The total for completion of all study visits is $600. If the doctor requests any additional visits, you will be paid $50 for each of them. Additional compensation for travel is available to partially cover expenses for hotels and/or airfare.

Who should I contact for more information?

Email: ccedresearch@cchmc.org

Cincinnati Center for Eosinophilic Disorders
The Division of Allergy and Immunology
Cincinnati Children’s Hospital Medical Center
3333 Burnet Ave.
Cincinnati, OH 45229-3039

Study Doctor:

Marc Rothenberg MD Cincinnati Children’s Hospital Medical Center  

Where can I find additional information?

ClinicalTrials.gov 

Eosinophilic Esophagitis (EoE) Study for Children At Least 12 Years Old and Adults

Why are we doing this research?

Cincinnati Children’s is conducting a research study, sometimes known as a clinical trial or clinical study, to determine the safety and effectiveness of a study drug called dupilumab for the treatment of EoE. 

Who can participate?

Children at least 12 years old and adults who:

  • Have a medical diagnosis of EoE

    and

  • Have had at least two episodes of difficulty swallowing per week in the month prior to beginning the study

Conditions

  • Adult Studies
  • Eosinophilic Disorders - EoE
  • Allergy - Food Allergy

What will happen in the study?

This study includes about 20 study visits over 18 months. Here are some of the things that will happen in this study:

You, as the study participant, or your child will:

  • Be randomly assigned (like flipping a coin) to receive either the investigational drug or placebo (inactive medication).
  • Receive one injection a week for 24 weeks during the first part of the study.
  • Be asked to complete a study diary to collect information about your or your child’s EoE symptoms
  • Have endoscopies with a biopsy 

If you or you child completes the first part of the study, you may have the opportunity to continue into the second part of the study. 

You will be given a consent form that thoroughly explains all of the details of the study. A member of the study staff will review the consent form with you and will be sure that all of your questions are answered.  

What are the good things that can happen from this research?

You or your child may not have a direct medical benefit. However, the information we learn from this study may help other people with EoE in the future.

What are the bad things that can happen from this research?

Possible risks and discomforts will be discussed with adults, parents and guardians interested in learning more about the study. 

Will you / your child be paid to be in this research study?

Participants will receive up to $1,400 for time and effort to complete the study.

Who should I contact for more information?

Email: ccedresearch@cchmc.org

Cincinnati Center for Eosinophilic Disorders
The Division of Allergy and Immunology
Cincinnati Children’s Hospital Medical Center
3333 Burnet Ave.
Cincinnati, OH 45229-3039

Study Doctor:

Marc Rothenberg MD
Cincinnati Children’s Hospital Medical Center  

Where can I find additional information?

ClinicalTrials.gov 

CEGIR OMEGA Study for Patients with Eosinophilic Esophagitis (EoE), Eosinophilic Gastritis (EoG), and Eosinophilic Colitis (EoC)

What is the purpose of this study?

The purpose of this observational research study is to find the best measures to define how well a person with eosinophilic disorder is doing. People with EoE, EoG, and EoC normally undergo endoscopy and/or colonoscopy where cells are collected for microscopic analysis. Treatments are then decided based on how the cells look.  We want to see if scores on standard questionnaires can give us an idea how well the person is doing.

Who can participate?

Children and adults ages 3-65 years that have been diagnosed with EoE, EoG, or EoC.

Details

General CEGIR OMEGA Description (PDF)
Adult (18-65 years) CEGIR OMEGA (PDF)
Pediatric (3-17 years) CEGIR OMEGA (PDF)

Who should I contact for more information?

ccedresearch@cchmc.org

Where can I find additional information?

https://www.rarediseasesnetwork.org/cms/CEGIR

CEGIR OMEGA Protocol Version 4.0

Eosinophilic Gastrointestinal Disorders 

Have you or your child been diagnosed with an Eosinophilic Gastrointestinal Disorder (EGID)?  The Cincinnati Center for Eosinophilic Disorders is conducting a research study designed to develop a better understanding and improved treatment plans for patients with an eosinophilic gastrointestinal disorders (EGID).

Who

Those of any age who have been diagnosed with an EGID.

What

Saliva samples and a brief medical history.

How

All study procedures will be done by phone, via mail and via the internet.

Why

To improve the understanding of the genetic factors of EGID.

Contact

If you are interested in participating or have any questions, please contact ccedresearch@cchmc.org

Family Tree Study

Have several people in your family been diagnosed with an Eosinophilic Gastrointestinal Disorder (EGID)? The Cincinnati Center for Eosinophilic Disorders is conducting a research study designed to develop a better understanding and improved treatment plans for patients with eosinophilic gastrointestinal disorders (EGID).

Who

Families who have more than one member diagnosed with an EGID, particularly those families with three generations of diagnoses (e.g. grandparent, parent, and child), or families with cousins who have been diagnosed. 

What

Saliva samples and a brief medical history will be collected. 

How

All study procedures will be done by phone, via mail, and via the internet.

Why

To better understand genetic factors that may influence how EGID is passed down through families.

Contact

If you are interested in participating or have any questions, please contact ccedresearch@cchmc.org

Twin Study  

Are you a twin diagnosed with an Eosinophilic Gastrointestinal Disorder (EGID)?   The Cincinnati Center for Eosinophilic Disorders is conducting a research study designed to develop a better understanding and improved treatment plans for patients with eosinophilic gastrointestinal disorders (EGID). 

Who

Identical and fraternal twins and multiple births of all ages with at least one sibling diagnosed with an EGID.

What

Saliva samples and a brief medical history will be collected.

How

All study procedures will be done by phone, via mail, and via the internet.

Why

To identify the genetic and environmental factors that contribute to the diagnosis of an EGID. 

Contact

If you are interested in participating or have any questions, please contact ccedresearch@cchmc.org

SOFEED Study for Patients with Eosinophilic Esophagitis (EoE)

What is the purpose of this study?

The purpose of this research study is to test the effects of two elimination dietary therapies—the 1 Food Elimination Diet (1FED) (Milk) vs. the 6 Food Elimination Diet (6FED) (Milk, Egg, Wheat, Soy, Peanut/tree nuts, and fish/shellfish) in patients diagnosed with EoE.  This study also aims to test participant’s response to swallowed glucocorticoids (Flovent) in participants who do not respond to the 6-Food elimination diet.  Flovent is a topical steroid (taken using an inhaler) approved by the FDA to treat asthma, but that is also used for patients with EoE.

Who can participate?

Adults ages 18-60 years that have been diagnosed with EoE.

Details

SOFEED Study (PDF)

Who should I contact for more information?

Email: ccedresearch@cchmc.org

Where can I find additional information?

https://www.rarediseasesnetwork.org/cms/CEGIR

Testing the Effectiveness of Losartan in Participants With EoE, With or Without a Connective Tissue Disorder 

The Cincinnati Center for Eosinophilic Disorders is conducting a research study to test whether losartan decreases the number of eosinophils in the esophagus of participants with active EoE, with or without a connective tissue disorder (CTD).

What

We are enrolling participants for a 4 month open label drug trial. This involves several visits to Cincinnati Children’s, blood draws, biopsies taken from EGD, and having vitals taken.

How

Participation will take place at Cincinnati Children’s, over the phone and through the mail.

Who

People with active EoE with or without a CTD

Contact

If you have questions or are interested in participating, contact ccedresearch@cchmc.org

Read More

Eosinophilic Esophagitis Medication Study

Eosinophilic Gastrointestinal Disorders with Connective Tissue Disorders

Have you been diagnosed with an Eosinophilic Gastrointestinal Disorder and / or a Connective Tissue Disorder? The Cincinnati Center for Eosinophilic Disorders is conducting a research study designed to develop a better understanding and improved treatment plans for patients diagnosed with eosinophilic gastrointestinal disorders (EGID).

Who

Those of all ages who have been diagnosed with an EGID and a CTD (e.g., Marfan’s Syndrome, Ehlers-Danlos Syndrome, Hypermobility Syndrome, etc.).

What

Saliva samples and a brief medical history will be collected.

How

All study procedures will be done by phone, via mail and via the internet.

Why

To better understand the relationship between EGID and connective tissue disorders.

Contact

If you are interested in participating or have any questions, please contact ccedresearch@cchmc.org , 513-803-3078

Children and Teens 6 to 17 years old with Eosinophilic Esophagitis (EoE) needed for 1 food vs 4 food elimination diet research study

 

Why are we doing this research?

Cincinnati Children’s is conducting a research study, sometimes known as a clinical trial or clinical study, to test and compare the effects (good and bad) of 2 elimination dietary therapies in people diagnosed with Eosinophilic Esophagitis, or EoE.

The 2 therapies are the 1 food (milk) elimination diet, or 1FED, versus the 4 food (milk, egg, wheat and soy) elimination diet, or 4FED.

We also want to see how someone with EoE responds to swallowed glucocorticoids (Flovent), when they did not respond to the 4 food elimination diet. A glucocorticoid is a steroid-like medicine that works to decrease inflammation.

Who can participate?

Children and Teens, 6 to 17 years old, who have been diagnosed with EoE, may be eligible for participation.

What will happen in the study?

If your child qualifies and you/your child decide to participate, your child will have up to 10 study visits. We will ask you to visit Cincinnati Children’s for some of the visits and for others study staff will call you.

This study consists of 2 phases, Phase I and Phase II, each lasting 3 months. Your child will be in this research study for at least 3 months (Phase 1) and no more than 6 months (Phase I and II).

The following is a list of some of the tests and procedures that may happen during the study:

  • Review of your child’s demographic information
  • Review of your child’s medical, medication and dietary history
  • Physical exam (including height, weight, blood pressure, heart rate, breathing rate and temperature)
  • Collection of blood samples
  • Collection of up to 4 extra esophageal biopsies (per endoscopy) for research: A small piece of tissue from your esophagus is taken during the endoscopy to measure your body’s response to diet and/or swallowed Flovent therapy.
  • Study questionnaires: The questionnaires will ask about your child’s quality of life, symptoms, dietary intake and how he or she is feeling overall (you/your child will complete these 8 times throughout the study).
  • Collection of urine sample for pregnancy test (for menstruating females only)
  • Prick skin testing for allergies: Small pricks are made on the skin where a drop of allergen is then placed via a solution. The area may become red, raised and itchy.
  • Patch skin testing: A solution with the possible allergen is placed on a pad and taped to the skin for 24 to 72 hours. If a red, raised and itchy area develops; the person is probably allergic to the allergen that is being tested.
  • Diet diary: Your child will be asked to complete diet diaries several times throughout the study.

During Phase I, your child will be randomly assigned (like flipping a coin) to 1 of the 2 diets (1FED or 4FED). The choice of which diet your child will be asked to follow is random, meaning that there is an equal chance of being in either group. Your child cannot choose which diet group he or she wants to be in for the study.

Your child’s participation in the study will end if his or her EoE improves after Phase I.

If your child is on the 1FED therapy in Phase I and his or her EoE does not improve, your child will switch to the 4FED in Phase II of this study.

If your child is on the 4FED therapy in Phase I and his or her EoE does not improve, your child will continue to Flovent in Phase II of this study. Not all participants will receive the study drug, Flovent. Flovent is an inhaler that spays the medication in the mouth, which is then swallowed and coats the esophagus.

Endoscopies (EGDs)

Your child will have 2 to 3 endoscopies (EGDs) during his or her time in the study. This is to test how your child’s EoE is doing.

EGDs are considered standard of care for individuals with EoE and are not study procedures. We ask your permission that your child’s doctor take 4 extra biopsies during the EGDs. We will review the results of the biopsy slides from the EGDs, as well as the slides themselves, to see if your child is getting better.

If your child has had an EGD with biopsies performed at Cincinnati Children’s or another institution within 4 weeks of his or her scheduled screening visit, he or she does not have to repeat the EGD. A research pathologist will review the slides as well as the results of your child’s most recent EGD. These will be used in part to determine your child’s study eligibility.

Diet and Other Medications

Throughout the study, if possible, your child should not eat foods that are not part of the diet he or she been assigned (1FED or 4FED) or take any medications that are not allowed. To help your child understand his or her diet, a Registered Dietitian will provide instructions. If there are changes to your child’s diet or medications at any time, you should contact a research staff member.

Unscheduled Visits

The study clinician may want to follow up on something from one of your child’s study visits. If this happens, the study team may ask your child to come in for extra visits.

Participants, parents and/or legal guardians interested in being part of this research will be given a consent form that thoroughly explains all of the details of the study. A member of the study staff will review the consent form with you and will be sure that all of your questions are answered.

What are the good things that can happen from this research?

Your child may not receive any direct medical benefits from participating in this research study. Other studies of swallowed fluticasone have shown some benefit for people with EoE. The effectiveness of the 1FED and 4FED elimination diet therapies has not been formally proven in EoE.

We hope the information learned from this research study may benefit other patients with EoE in the future.

What are the bad things that can happen from this research?

Your child may experience some risks during this study. Risks may include oozing at the site of the tissue sample; development of a yeast infection (oral thrush) in the mouth or esophagus; and pain, itching, and/or bruising at the location of the blood sample or skin testing for allergies. There may be other risks as well.

A detailed list of possible side effects will be provided to those participants, parents and/or legal guardians interested in knowing more about this study.

A trained professional will manage the treatment for your child’s EoE during the research study.

Will you/your child be paid to be in this research study?

Participants will receive $180 for their time, effort and travel for this study.

Who should I contact for more information?

Email: ccedresearch@cchmc.org

Eosinophilic Gastritis (EoG) Study for Adults 18 to 80 Years Old

What

A study to determine if a new drug is safe, effective and tolerable for people diagnosed with Eosinophilic Gastritis (with or without Eosinophilic Gastroenteritis). The study involves about 11 visits to the clinic and may take up to six months to complete.

Who

Men and women ages 18 to 80 years old with Eosinophilic Gastritis (with or without Eosinophilic Gastroenteritis)

Pay

Participants will receive up to $4,000 for for time, effort and travel.

Who should I contact for more information?

Email: ccedresearch@cchmc.org

Where can I find additional information?

ClinicalTrials.gov

CEGIR

The Consortium of Eosinophilic Gastrointestinal Disease Researchers (CEGIR) is dedicated to improving the lives of individuals with eosinophilic gastrointestinal disorders through innovative research, clinical expertise and education via collaborations between scientists, health care providers, patients, and professional organizations. CEGIR is part of the Rare Diseases Clinical Research Network (RDCRN) and has a contact registry. Consider joining today.

Read More
Mother with son.
Our clinical trials are not only for children. See the Ongoing Clinical Trials descriptions on this page for specifics of who are eligible to participate.